曲氟尿苷替匹嘧啶治疗 Regorafenib 治疗不可及的转移性结直肠癌患者的临床结局。

Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.

机构信息

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan;

出版信息

Anticancer Res. 2021 Apr;41(4):2203-2207. doi: 10.21873/anticanres.14996.

DOI:10.21873/anticanres.14996

PMID:33813435

Abstract

BACKGROUND/AIM: In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear.

PATIENTS AND METHODS

The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities.

RESULTS

Among the 27 patients who received trifluridine/tipiracil, many had comorbidities of deep venous thrombosis or hemorrhage. The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. The median overall survival was 7.7 months in 19 patients without subsequent regorafenib. Grade 3 or higher toxicities were found in 51% of patients. No treatment discontinuation because of comorbidities was observed.

CONCLUSION

Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib.

摘要

背景/目的：在转移性结直肠癌（mCRC）的后线治疗中，由于合并血栓形成、出血或心脏事件等并发症，患者往往难以使用瑞戈非尼，因此常选择替比嘧啶/曲氟尿苷。然而，替比嘧啶/曲氟尿苷在这些患者中的安全性和疗效尚不清楚。

患者和方法

对因合并症而不适合使用瑞戈非尼的患者进行了替比嘧啶/曲氟尿苷的临床疗效回顾性研究。

结果

在接受替比嘧啶/曲氟尿苷治疗的 27 例患者中，许多患者存在深静脉血栓形成或出血等合并症。中位总生存期为 12.4 个月，中位无进展生存期为 2.8 个月。19 例未接受后续瑞戈非尼治疗的患者的中位总生存期为 7.7 个月。51%的患者出现 3 级或更高级别的毒性。未观察到因合并症而停止治疗的情况。